-
Mashup Score: 0Management of CLTI in an Era of BEST-CLI and BASIL-2 - 1 month(s) ago
Dr. Alik Farber discusses his ISET 2024 presentation on the BEST-CLI and BASIL-2 trials and how to best manage patients with CLTI in the wake of these trials.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 0Management of CLTI in an Era of BEST-CLI and BASIL-2 - 1 month(s) ago
Dr. Alik Farber discusses his ISET 2024 presentation on the BEST-CLI and BASIL-2 trials and how to best manage patients with CLTI in the wake of these trials.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Cardiology News and JournTweet-
In this video, Alik Farber, MD, discusses his ISET 2024 presentation on how to best manage patients with #CLTI in the wake of the BEST-CLI and BASIL-2 randomized controlled trials. Dr. Farber was the National Principal Investigator of the BEST-CLI trial. https://t.co/TJxzjvaJAW https://t.co/bBClWvZSHo
-
-
Mashup Score: 3Current Studies of the MicroStent System for Treating PAD and CLI - 3 month(s) ago
Vascular Disease Management spoke with Dr. Robert E. Beasley, who is the National Principal Investigator for the STAND Trial, to discuss the 2 current clinical studies in patients with chronic limb-threatening ischemia.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 0
The article emphasizes that BTK interventions are rarely speedy or easy, and encourages operator patience and commitment.
Source: www.tctmd.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0Source: YouTubeCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0PROMISE-ing Updates for Percutaneous Deep Vein Arterialization - 10 month(s) ago
Transcatheter arterialization of the deep veins is safe and effective, and offers a potential new treatment option for patients facing amputation.
Source: HMP Global Learning NetworkCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0SCAI: New Analysis of Critical Limb-Ischemia Patients Places BEST-CLI Trial Into Context Within Real-World Setting - 11 month(s) ago
The new study sought to analyze a broader clinical population by identifying all Medicare beneficiaries between 2016-2019 and aged 65-85 years with a diagnosis of CLTI who underwent endovascular or surgical revascularization.
Source: HMP Global Learning NetworkCategories: Cardiology News and Journals, Latest HeadlinesTweet-
SCAI: New Analysis of Critical Limb-Ischemia Patients Places BEST-CLI Trial Into Context Within Real-World Setting The new study sought to analyze a broader clinical population of #CLTI patients who underwent endovascular or surgical revascularization: https://t.co/fwzTw463OB https://t.co/cvSpnoEJk0
-
-
Mashup Score: 0What Works, What’s Noise? Novel Approaches Offer Hope in CLTI - 11 month(s) ago
Getting good data on wound healing and its impact on CLTI patients’ lives is an ongoing challenge, says Raghu Kolluri.
Source: TCTMD.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0Next Horizons in BTK Disease Research - Endovascular Today - 11 month(s) ago
Priorities for CLI/CLTI research, where progress needs to be made regarding limb salvage disparities, the role of artificial intelligence in individualizing care, and what the multidisciplinary care team of the future should look like.
Source: Endovascular TodayCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0May 2023 Issue - Endovascular Today - 11 month(s) ago
News and information on minimally invasive vascular disease therapies, covering peripheral vascular disease, aneurysms, stroke, hypertension, dialysis access, and venous issues.
Source: Endovascular TodayCategories: Cardiology News and Journals, Latest HeadlinesTweet
In this video, Alik Farber, MD, discusses his ISET 2024 presentation on how to best manage patients with #CLTI in the wake of the BEST-CLI and BASIL-2 randomized controlled trials. Dr. Farber was the National Principal Investigator of the BEST-CLI trial. https://t.co/TJxzjvaJAW https://t.co/bBClWvZSHo